Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421104 · ClinicalTrials.gov registry record
Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,576
- Enrollment target
NCT05421104 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,576 participants.
The verdict
NCT05421104 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,576 participants
- Enrollment target
Study Summary
This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.
Interventions
- OTHER Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,576 participants |
| Start Date | 2020-11-27 |
| Est. Completion | 2021-06-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05421104
The ClinicalTrials.gov registry entry for NCT05421104 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,576 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05421104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05421104 about?
NCT05421104 is a clinical study titled "Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.". This was an analytical and descriptive, non-interventional, retrospective cohort study of PV patients aged ≥ 18 years in the US using a secondary data source, Optum EHR database.
What is the current status of trial NCT05421104?
This trial is currently completed. The enrollment target is 1,576 participants. The study started on 2020-11-27. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT05421104?
The interventions under investigation include: Ruxolitinib (OTHER).
Who is sponsoring clinical trial NCT05421104?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.